Adalimumab is used to treat various autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. It also helps manage moderate to severe psoriasis, hidradenitis suppurativa, juvenile idiopathic arthritis, and non-infectious uveitis by reducing inflammation and symptoms.

Adalimumab works by blocking TNF-?, a protein that causes inflammation. By preventing TNF-? activity, it reduces inflammation and helps control symptoms of autoimmune diseases.

Adalimumab is given as a subcutaneous injection, usually in the thigh or abdomen, with rotation of injection sites to prevent irritation. It comes in pre-filled pens or syringes for self-use, and the dosing schedule varies by the condition being treated.

Adalimumab can cause injection site reactions, headache, nausea, rash, and mild infections. It may also increase the risk of serious infections like TB due to immune suppression. Rarely, it can affect the liver, blood cells, nervous system, or heart. Regular monitoring is important, and any signs of infection or unusual symptoms should be reported to a doctor.

Adalimumab should not be used in patients allergic to it or those with severe active infections like TB or sepsis. Screening for latent infections is required before treatment. Caution is needed in people with chronic infections, heart failure, or demyelinating diseases. Live vaccines should be avoided, and regular monitoring of liver function, blood counts, and infection signs is recommended. Use in pregnancy or breastfeeding should be based on medical advice.

Adalimumab is a highly effective biologic that targets TNF-? to manage autoimmune and inflammatory diseases. It has greatly improved outcomes in conditions like rheumatoid arthritis, Crohn’s disease, and psoriasis. Although monitoring is important due to infection risks, it remains a valuable and widely used treatment when guided by proper medical care.

Adalimumab is a fully human monoclonal antibody, unlike infliximab (a chimeric antibody) and etanercept (a fusion protein). This fully human structure reduces the risk of immunogenicity and allergic reactions compared to chimeric or partially humanized antibodies.

Yes, Adalimumab is often used in combination with methotrexate, especially in rheumatoid arthritis, to enhance therapeutic efficacy and reduce the development of anti-drug antibodies. However, combining multiple immunosuppressants increases the risk of infections and requires close monitoring.

The development of anti-Adalimumab antibodies can reduce the drug's efficacy and increase the risk of adverse reactions. Concurrent use of immunomodulators like methotrexate may help reduce the formation of these antibodies.

Patients must be screened for latent or active tuberculosis using a tuberculin skin test or IGRA. Screening for hepatitis B, hepatitis C, and HIV may also be considered based on risk factors. Baseline CBC, liver function tests, and chest X-ray are often recommended.

Long-term use may increase the risk of serious infections, malignancies (such as lymphoma or skin cancers), autoimmune phenomena, and demyelinating disorders. Regular follow-up and patient education are essential for early detection of these risks.

Adalimumab is classified as pregnancy category B. It may be used during pregnancy when the benefits outweigh the risks, especially during the first two trimesters. The drug can cross the placenta in the third trimester, so infant vaccination schedules (especially live vaccines) may need adjustment. Caution is also advised during breastfeeding.

Adalimumab must be stored refrigerated at 2°C to 8°C (36°F to 46°F) and protected from light. It should not be frozen.

By neutralizing TNF-?, Adalimumab disrupts granuloma formation and maintenance, which are crucial for containing latent TB. This suppression can lead to reactivation of latent tuberculosis infections, hence the need for screening and possible prophylactic treatment prior to starting therapy.

No dose adjustment is generally required for patients with renal or hepatic impairment, but such patients should be monitored closely as safety data is limited.

Loss of response can be due to immunogenicity, disease progression, or pharmacokinetic changes. Management strategies include dose escalation, shortening the dosing interval, switching to another TNF inhibitor, or changing to a biologic with a different mechanism of action, such as IL-6 or IL-17 inhibitors.